<SEC-DOCUMENT>0002002390-26-000005.txt : 20260318
<SEC-HEADER>0002002390-26-000005.hdr.sgml : 20260318
<ACCEPTANCE-DATETIME>20260318142332
ACCESSION NUMBER:		0002002390-26-000005
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260318
FILED AS OF DATE:		20260318
DATE AS OF CHANGE:		20260318

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Abele Stefan Andreas
		CENTRAL INDEX KEY:			0002002390
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40010
		FILM NUMBER:		26768006

	MAIL ADDRESS:	
		STREET 1:		C/O PHARVARIS N.V.
		STREET 2:		EMMY NOETHERWEG 2
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			2333 BK

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pharvaris N.V.
		CENTRAL INDEX KEY:			0001830487
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7
		BUSINESS PHONE:		31 (0)71 203 6410

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pharvaris, B.V.
		DATE OF NAME CHANGE:	20201029
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0607</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2026-03-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001830487</issuerCik>
        <issuerName>Pharvaris N.V.</issuerName>
        <issuerTradingSymbol>PHVS</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002002390</rptOwnerCik>
            <rptOwnerName>Abele Stefan Andreas</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>1 CRANBERRY HILL SUITE 400</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>LEXINGTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02421</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Technical Ops Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>43942</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>28.00</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2036-03-03</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>60000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>16.05</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-04-12</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>60000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>22.31</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-04-11</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>40000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>16.40</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-11-15</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>89500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows:
-20,000 RSUs from an award granted March 3, 2026 of which 25% vested March 3, 2027 with the remainder vesting monthly thereafter;
-15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter;
-6,849 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.</footnote>
        <footnote id="F2">25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.</footnote>
        <footnote id="F3">25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.</footnote>
        <footnote id="F4">25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.</footnote>
        <footnote id="F5">25% of the option vested on November 15, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Marnus Nel, Attorney-in-Fact for Stefan Abele</signatureName>
        <signatureDate>2026-03-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.POA
<SEQUENCE>2
<FILENAME>phvs-ex24_poa.htm
<DESCRIPTION>EX-24.POA
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-17T10:38:40.8331+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-24.POA</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</font></h1><p style="margin-left:0.093%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2, 2026</font></p><p style="text-indent:8.779%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints each of David Nassif, Marnus Nel, and Skyler Wallace, acting individually, as the undersigned&#x2019;s true and lawful attorney-in-fact and agent, with full power and authority, including substitution and revocation, as hereinafter described on behalf of and in the name, place and stead of the undersigned to:</font></p><div class="item-list-element-wrapper" style="margin-left:1.204%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10%;min-width:5.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.529576096198226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">execute for and on behalf of the undersigned, in the undersigned&#x2019;s capacity as a director, officer or beneficial owner of shares of stock of Pharvaris N.V., a Dutch public limited liability company (naamloze vennootschap) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), any Schedule 13D or Schedule 13G, and any amendments, supplements or exhibits thereto (including any joint filing agreements) required to be filed by the undersigned under Section 13 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), any Form 3, 4 and 5 and any amendments, supplements or exhibits thereto required to be filed by the undersigned under Section 16(a) of the Exchange Act, as well as notices on Form 144 and amendments thereto, filed pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.667%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.040288725801094%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek or obtain, as the undersigned&#x2019;s representative and on the undersigned&#x2019;s behalf, information on transactions in the Company&#x2019;s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to any attorney-in-fact and further approves and ratifies any such release of information;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, and any amendments thereto, Form 3, 4 or 5, and any amendments thereto, notices on Form 144 and amendments thereto, or any other required report relating to any of the foregoing and timely file such notices, forms or reports with the U.S. Securities and Exchange Commission and any stock exchange on which the stock of the Company is then listed; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.13%;display:flex;margin-top:6.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.545509161910484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in each such attorney-in-fact&#x2019;s discretion.</font></div></div><p style="text-indent:8.785%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.315%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned hereby acknowledges that (a) the foregoing attorneys-in-fact are serving in such capacity at the request of the undersigned; (b) this Power of Attorney authorizes,</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but does not require, each such attorney-in-fact to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information; (c) any documents prepared and/or executed by any attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact, in his or her sole discretion, deems necessary or advisable;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) neither the Company nor any attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act or Securities Act, as applicable, (ii) any liability of the undersigned for any failure to comply with such requirements,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act, if applicable, or (iv) any liability resulting from a failure to qualify for the safe harbor under Rule 144; and (e) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned&#x2019;s obligations under the Exchange Act or Securities Act, including, without limitation, the reporting requirements under Section 13 and Section 16 of the Exchange Act or Rule 144 promulgated under the Securities Act, as applicable.</font></p><p style="text-indent:8.78%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Power of Attorney shall remain in full force and effect (and shall survive, if necessary, by incapacity and/or death) until the undersigned is no longer required to file Schedule 13D or Schedule 13G, Forms 3, 4 or 5, notices on Form 144, or any amendments, supplements or exhibits to any of the foregoing with respect to the undersigned&#x2019;s holdings of, and transactions in, securities issued by the Company, unless earlier revoked as to any attorney-in-fact by the undersigned in a signed writing delivered to such attorney-in-fact.</font></p><p style="margin-left:0.12%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature Page to Follow]</font></p><p style="margin-left:0.08%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* * * * *</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.734%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first written above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:53.333%;text-indent:14.598%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1%;text-align:left;"><img src="img151619395_0.gif" alt="img151619395_0.gif" style="width:145px;height:70px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img151619395_0.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img151619395_0.gif
M1TE&.#EAX0'J /<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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@$C0&Y3T%Y??9Y8H$YF 6YF$FYF(VYF-&YF1NQH   #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
